Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

The enhanced antitumor activity of bispecific antibody targeting PD-1/PD-L1 signaling

Anti-PD-L1-Based Bispecific Antibodies Targeting Co-Inhibitory and Co-Stimulatory Molecules for Cancer Immunotherapy

Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy

Polymeric PD1/PDL1 Bispecific Antibody Enhances Immune Checkpoint Blockade Therapy

Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities

Bispecific Antibodies, Immune Checkpoint Inhibitors, and Antibody−Drug Conjugates Directing Antitumor Immune Responses: Challenges and Prospects

Bispecific Antibodies Targeting Immunomodulator Y Checkpoints for Cancer Therapy

A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy

Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy

Advances in the study of CD47‐based bispecific antibody in cancer immunotherapy

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy

Targeting dendritic cells with a PD-L1 based bispecific antibody rejuvenates specific anti-tumor T cells

A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function

Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

Optimization of Cancer Immunotherapy on the Basis of Programmed Death Ligand‐1 Distribution and Function